{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T07:09:51Z","timestamp":1782112191414,"version":"3.54.5"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Recent genetic and molecular findings have impacted the diagnosis, prognosis, and in some instances, treatment strategies for children with pediatric central nervous system tumors. Herein, we review the most up-to-date molecular findings and how they have impacted tumor classification and clinical care.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>It is now recognized that aberrations of the mitogen-activated protein kinase pathway are present in the majority of pediatric low-grade glioma. Also, there has been the identification of recurrent histone H3 K27M mutations in diffuse intrinsic pontine and other midline gliomas. Medulloblastoma is now divided into four molecular subgroups with distinct characteristics and prognoses. The classification of other unique embryonal tumors is also highlighted. Finally, we present the newest classification of ependymoma; supratentorial ependymomas comprise two subtypes based on expression of the chromosome 11 Open Reading Frame 95\u2013reticuloendotheliosis Viral Oncogene Homolog A or yes-associated protein 1 fusion, whereas posterior fossa ependymomas are divided into two distinct molecular subgroups, posterior fossa-A and posterior fossa-B.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>These advances in the molecular classification of pediatric central nervous system tumors have not only assisted in diagnoses, but they have led to a new era of tumor classification and prognostication. They also have served as drivers for the evaluation of new targeted therapies based upon molecular aberrations with the hope for improved survival outcomes for our patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000000975","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T03:00:25Z","timestamp":1607137225000},"page":"26-32","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Advances in the classification and treatment of pediatric brain tumors"],"prefix":"10.1097","volume":"33","author":[{"given":"Jason","family":"Fangusaro","sequence":"first","affiliation":[{"name":"Children's Healthcare of Atlanta, Emory University and the Aflac Cancer Center, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratiti","family":"Bandopadhayay","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Boston Children's Cancer and Blood Disorders Center"},{"name":"Department of Pediatrics, Harvard Medical School"},{"name":"Broad Institute of MIT and Harvard, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,4]]},"reference":[{"key":"R1-20250730","first-page":"v1","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012\u20132016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neurooncology"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.2009.27.4324","article-title":"Medulloblastoma comprises four distinct molecular variants","volume":"29","author":"Northcott","year":"2010","journal-title":"J Clin Oncol"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00401-012-0958-8","article-title":"Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas","volume":"123","author":"Kool","year":"2012","journal-title":"Acta Neuropathol"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00401-011-0922-z","article-title":"Molecular subgroups of medulloblastoma: the current consensus","volume":"123","author":"Taylor","year":"2012","journal-title":"Acta Neuropathol"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.2010.28.5148","article-title":"Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome","volume":"29","author":"Cho","year":"2011","journal-title":"J Clin Oncol"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature11284","article-title":"Dissecting the genomic complexity underlying medulloblastoma","volume":"488","author":"Jones","year":"2012","journal-title":"Nature"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature11327","article-title":"Subgroup-specific structural variation across 1,000 medulloblastoma genomes","volume":"488","author":"Northcott","year":"2012","journal-title":"Nature"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat Genet"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ng.2611","article-title":"Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nature genetics"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/ng.3500","article-title":"MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism","volume":"48","author":"Bandopadhayay","year":"2016","journal-title":"Nat Genet"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2016.01.015","article-title":"New brain tumor entities emerge from molecular classification of CNS-PNETs","volume":"164","author":"Sturm","year":"2016","journal-title":"Cell"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/d41586-018-01648-4","article-title":"Landscapes of childhood tumours","volume":"555","author":"Bandopadhayay","year":"2018","journal-title":"Nature"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Gr\u00f6bner","year":"2018","journal-title":"Nature"},{"key":"R16-20250730","first-page":"986","article-title":"Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors","volume":"19","author":"Ramkissoon","year":"2017","journal-title":"Neurooncology"},{"key":"R17-20250730","first-page":"699","article-title":"Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy","volume":"19","author":"Kline","year":"2016","journal-title":"Neurooncology"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/pbc.24958","article-title":"Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database","volume":"61","author":"Bandopadhayay","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","article-title":"Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group","volume":"30","author":"Ater","year":"2012","journal-title":"J Clin Oncol"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","article-title":"Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas","volume":"37","author":"Ryall","year":"2020","journal-title":"Cancer Cell"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40478-020-00898-6","article-title":"FGFR- gene family alterations in low-grade neuroepithelial tumors","volume":"8","author":"Bale","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"8188","DOI":"10.1073\/pnas.1300252110","article-title":"Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1","volume":"110","author":"Ramkissoon","year":"2013","journal-title":"PNAS"},{"key":"R24-20250730","first-page":"273","article-title":"Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course","volume":"48","author":"Wefers","year":"2019","journal-title":"Acta Neuropathol"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00401-016-1539-z","article-title":"Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology","volume":"131","author":"Qaddoumi","year":"2016","journal-title":"Acta Neuropathol"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev-genet-120417-031642","article-title":"The power of human cancer genetics as revealed by low-grade gliomas","volume":"53","author":"Jones","year":"2019","journal-title":"Annu Rev Genet"},{"key":"R28-20250730","first-page":"153","article-title":"Pediatric high-grade glioma: biologically and clinically in need of new thinking","volume":"19","author":"Jones","year":"2017","journal-title":"Neurooncology"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin re-modelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric nonbrainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat Genet"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/ng.2936","article-title":"Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations","volume":"46","author":"Buczkowicz","year":"2014","journal-title":"Nat Genet"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/ng.2950","article-title":"Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma","volume":"46","author":"Fontebasso","year":"2014","journal-title":"Nat Genet"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1158\/2159-8290.CD-19-1030","article-title":"Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes","volume":"10","author":"Clarke","year":"2020","journal-title":"Cancer Discov"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1038\/s41467-019-12187-5","article-title":"Alterations in ALK\/ROS1\/NTRK\/MET drive a group of infantile hemispheric gliomas","volume":"10","author":"Stucklin","year":"2019","journal-title":"Nat Commun"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00401-015-1405-4","article-title":"Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers","volume":"129","author":"Korshunov","year":"2015","journal-title":"Acta Neuropathol"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"e17948","DOI":"10.1371\/journal.pone.0017948","article-title":"BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications","volume":"6","author":"Dias-Santagata","year":"2011","journal-title":"PLoS One"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bpa.12639","article-title":"The genetic landscape of anaplastic pleomorphic xanthoastrocytoma","volume":"29","author":"Phillips","year":"2018","journal-title":"Brain Pathol (Zurich, Switzerland)"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11060-017-2568-8","article-title":"Rethinking childhood ependymoma: a retrospective, multicenter analysis reveals poor long-term overall survival","volume":"135","author":"Marinoff","year":"2017","journal-title":"J Neurooncol"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-016-1643-0","article-title":"The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants","volume":"133","author":"Pajtler","year":"2017","journal-title":"Acta Neuropathol"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccell.2015.04.002","article-title":"Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups","volume":"27","author":"Pajtler","year":"2015","journal-title":"Cancer Cell"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00401-018-1888-x","article-title":"Heterogeneity within the PF-EPN-B ependymoma subgroup","volume":"136","author":"Cavalli","year":"2018","journal-title":"Acta Neuropathol"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1200\/JCO.2006.06.4980","article-title":"Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma","volume":"24","author":"Packer","year":"2006","journal-title":"J Clin Oncol"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1200\/JCO.2009.27.4324","article-title":"Medulloblastoma comprises four distinct molecular variants","volume":"29","author":"Northcott","year":"2011","journal-title":"J Clin Oncol"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00401-011-0846-7","article-title":"Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct","volume":"122","author":"Northcott","year":"2011","journal-title":"Acta Neuropathol"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1200\/JCO.2012.48.5052","article-title":"Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma","volume":"31","author":"Zhukova","year":"2013","journal-title":"J Clin Oncol"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/nature09587","article-title":"Subtypes of medulloblastoma have distinct developmental origins","volume":"468","author":"Gibson","year":"2010","journal-title":"Nature"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/S1470-2045(13)70449-2","article-title":"Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis","volume":"14","author":"Ramaswamy","year":"2013","journal-title":"Lancet Oncol"},{"key":"R49-20250730","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s00401-016-1569-6","article-title":"Risk stratification of childhood medulloblastoma in the molecular era: the current consensus","volume":"131","author":"Ramaswamy","year":"2016","journal-title":"Acta Neuropathol"},{"key":"R50-20250730","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1200\/JCO.2014.60.1591","article-title":"Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032","volume":"33","author":"Robinson","year":"2015","journal-title":"J Clin Oncol"},{"key":"R51-20250730","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3171\/jns.1996.85.1.0056","article-title":"Central nervous system atypical teratoid\/rhabdoid tumors of infancy and childhood: definition of an entity","volume":"85","author":"Rorke","year":"1996","journal-title":"J Neurosurg"},{"key":"R52-20250730","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.2008.18.7724","article-title":"Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor","volume":"27","author":"Chi","year":"2009","journal-title":"J Clin Oncol"},{"key":"R53-20250730","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1172\/JCI64400","article-title":"A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers","volume":"122","author":"Lee","year":"2012","journal-title":"J Clin Invest"},{"key":"R54-20250730","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/pbc.24315","article-title":"Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors","volume":"59","author":"Kieran","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R55-20250730","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/pbc.22831","article-title":"Spectrum of SMARCB1\/INI1 mutations in familial and sporadic rhabdoid tumors","volume":"56","author":"Eaton","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R56-20250730","doi-asserted-by":"crossref","first-page":"412","DOI":"10.4161\/cbt.8.5.8019","article-title":"The role of SMARCB1\/INI1 in the development of rhabdoid tumors","volume":"8","author":"Roberts","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"R57-20250730","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccell.2016.02.001","article-title":"Atypical teratoid\/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes","volume":"29","author":"Johann","year":"2016","journal-title":"Cancer Cell"},{"key":"R58-20250730","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ccell.2016.11.003","article-title":"Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors","volume":"30","author":"Torchia","year":"2016","journal-title":"Cancer Cell"},{"key":"R59-20250730","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S1470-2045(15)70114-2","article-title":"Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis","volume":"16","author":"Torchia","year":"2015","journal-title":"Lancet Oncol"},{"key":"R61-20250730","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/ng.2849","article-title":"Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR","volume":"46","author":"Kleinman","year":"2014","journal-title":"Nat Genet"},{"key":"R62-20250730","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00401-020-02182-2","article-title":"ETMR: a tumor entity in its infancy","volume":"140","author":"Lambo","year":"2020","journal-title":"Acta Neuropathol"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:13:40Z","timestamp":1753899220000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,4]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000975","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,4]]}}}